

1) Which of the following statements is true regarding the use of simvastatin 80 mg?

- a. Patients who have been taking simvastatin 60 mg and experienced no signs or symptoms of myopathy can be increased to an 80 mg dose of simvastatin
- b. Simvastatin 80 mg should no longer be used due to the high risk of myopathy and rhabdomyolysis and patients should be switched to an alternative hyperlipidemia medication
- c. Patients who have been taking simvastatin 80 mg for at least twelve months and experienced no signs or symptoms of myopathy can continue on this dose
- d. Simvastatin 80 mg is contraindicated in those at high risk of myopathy, including females and the elderly.

2) Which of the following medications was recently added to the list of drugs that are contraindicated with concomitant statin therapy?

- a. Verapamil
- b. Gemfibrozil
- c. Amlodopine
- d. Ranolazine

3) What is the maximum dose of simvastatin that can be taken in combination with Diltiazem?

- a. 10 mg
- b. 20 mg
- c. 40 mg
- d. It is contraindicated

4) Which of the following statements is TRUE regarding a recent meta-analysis observing the effects of high-dose statins on diabetes risk

- a. The results showed that those on moderate-dose statins are at increased risk of developing diabetes.
- b. There were fewer cases of developing diabetes than there were cardiovascular events prevented due to the use of high-dose statins.
- c. The risk of using high-dose statins appears to be greater than the benefits in those with cardiovascular disease.
- d. The evidence did not show any increase risk of diabetes with the use of statins.

5) The results of the AIM-HIGH trial suggest that niacin does which of the following:

- a. Causes increased risk of rhabdomyolysis in those with a history of cardiovascular disease
- b. Significantly decreases risk of major adverse cardiovascular events in those with a history of cardiovascular disease
- c. Has little to no effect on HDL and TG's.
- d. Has little to no effect on preventing major adverse cardiovascular events in those with a history of cardiovascular disease

6) Anacetrapib is a CETP inhibitor which showed great efficacy for lowering LDL and raising HDL in which of the following clinical trials?

- a. ILLUMINATE
- b. ACCORD
- c. DEFINE
- d. SEARCH

7) Which of the following lab values was not affected by anacetrapib?

- a. Apolipoprotein B
- b. LDL
- c. HDL
- d. hs-CRP

8) What is the mechanism of action of the emerging hyperlipidemia medication known as darapladib?

- a. Inhibits Lp-PLA2 and prevents plaque rupture
- b. Mediates the transfer of cholesterol and triglycerides between lipoprotein particles
- c. Inhibits the absorption of cholesterol and related phytosterols by the small intestine
- d. Inhibits peripheral lipolysis and decreases hepatic extraction of free fatty acids

9) What trial is currently underway to test the safety and efficacy of darapladib in patients with coronary artery disease?

- a. IBIS-2
- b. STABILITY
- c. SOLID-TIMI 52
- d. REVEAL

10) When is the expected release date of the NCEP ATP IV guidelines?

- a. Fall 2011
- b. Spring 2012
- c. Summer 2013
- d. Winter 2015

This activity is a **FREE** service to members of the Kentucky Pharmacists Association. The fee for non-members is \$30. The fee for duplicate certificates is \$5. **Please send a self addressed, stamped envelope to KPERF, 1228 US 127 South, Frankfort, KY 40601.**

Expiration Date: September 20, 2014

Successful Completion: Score of 80% will result in **1.0 contact hour or 0.10 CEUs.**
Participants who score less than 80% will be notified and permitted one re-examination.

August 2011– Disease State Management: Hyperlipidemia Treatment Updates
TECHNICIANS ANSWER SHEET. Not ACPE approved for Technicians.

Name _____ KY Cert. # _____

Address _____

PLEASE CIRCLE THE APPROPRIATE ANSWERS:

- | | | | | |
|------------|------------|------------|------------|-------------|
| 1. A B C D | 3. A B C D | 5. A B C D | 7. A B C D | 9. A B C D |
| 2. A B C D | 4. A B C D | 6. A B C D | 8. A B C D | 10. A B C D |

Met my educational needs	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Figures and tables were useful	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Achieve the stated objectives	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Posttest was appropriate	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Was well written	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Commercial bias was present	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Is relevant to my practice	<input type="checkbox"/> Yes	<input type="checkbox"/> No			

I hereby certify that I completed this self-study program independently and without assistance from any other party.

Signature _____ Date _____

August 2011– Disease State Management: Hyperlipidemia Treatment Updates
Universal Activity # 0143-0000-11-008-H01-P
PHARMACISTS ANSWER SHEET

Name _____ KY Lic. # _____

Address _____

PLEASE CIRCLE THE APPROPRIATE ANSWERS:

- | | | | | |
|------------|------------|------------|------------|-------------|
| 1. A B C D | 3. A B C D | 5. A B C D | 7. A B C D | 9. A B C D |
| 2. A B C D | 4. A B C D | 6. A B C D | 8. A B C D | 10. A B C D |

Information presented in the activity:

Met my educational needs	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Figures and tables were useful	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Achieve the stated objectives	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Posttest was appropriate	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Was well written	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Commercial bias was present	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Is relevant to my practice	<input type="checkbox"/> Yes	<input type="checkbox"/> No			

Unmet Objectives: _____

I hereby certify that I completed this self-study program independently and without assistance from any other party.

Signature _____ Date _____

